106 related articles for article (PubMed ID: 17445215)
1. Different mechanisms can lead to the same altered HLA class I phenotype in tumors.
Rodriguez T; Aptsiauri N; Méndez R; Jimenez P; Ruiz-Cabello F; Garrido F
Tissue Antigens; 2007 Apr; 69 Suppl 1():259-63. PubMed ID: 17445215
[TBL] [Abstract][Full Text] [Related]
2. Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer.
Romero JM; Jiménez P; Cabrera T; Cózar JM; Pedrinaci S; Tallada M; Garrido F; Ruiz-Cabello F
Int J Cancer; 2005 Feb; 113(4):605-10. PubMed ID: 15455355
[TBL] [Abstract][Full Text] [Related]
3. LOH at 6p21.3 region and HLA class I altered phenotypes in bladder carcinomas.
Maleno I; Romero JM; Cabrera T; Paco L; Aptsiauri N; Cozar JM; Tallada M; López-Nevot MA; Garrido F
Immunogenetics; 2006 Jul; 58(7):503-10. PubMed ID: 16705407
[TBL] [Abstract][Full Text] [Related]
4. Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors.
Cabrera CM; Jiménez P; Cabrera T; Esparza C; Ruiz-Cabello F; Garrido F
Tissue Antigens; 2003 Mar; 61(3):211-9. PubMed ID: 12694570
[TBL] [Abstract][Full Text] [Related]
5. MUTYH-associated polyposis carcinomas frequently lose HLA class I expression - a common event amongst DNA-repair-deficient colorectal cancers.
de Miranda NF; Nielsen M; Pereira D; van Puijenbroek M; Vasen HF; Hes FJ; van Wezel T; Morreau H
J Pathol; 2009 Sep; 219(1):69-76. PubMed ID: 19462419
[TBL] [Abstract][Full Text] [Related]
6. Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers.
Kloor M; Becker C; Benner A; Woerner SM; Gebert J; Ferrone S; von Knebel Doeberitz M
Cancer Res; 2005 Jul; 65(14):6418-24. PubMed ID: 16024646
[TBL] [Abstract][Full Text] [Related]
7. Expression of transporters associated with antigen processing and human leucocyte antigen class I in malignant melanoma and its association with prognostic factors.
Tao J; Li Y; Liu YQ; Li L; Liu J; Shen X; Shen GX; Tu YT
Br J Dermatol; 2008 Jan; 158(1):88-94. PubMed ID: 17999701
[TBL] [Abstract][Full Text] [Related]
8. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
Maeurer MJ; Gollin SM; Storkus WJ; Swaney W; Karbach J; Martin D; Castelli C; Salter R; Knuth A; Lotze MT
Clin Cancer Res; 1996 Apr; 2(4):641-52. PubMed ID: 9816214
[TBL] [Abstract][Full Text] [Related]
9. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome.
Meissner M; Reichert TE; Kunkel M; Gooding W; Whiteside TL; Ferrone S; Seliger B
Clin Cancer Res; 2005 Apr; 11(7):2552-60. PubMed ID: 15814633
[TBL] [Abstract][Full Text] [Related]
10. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors.
Facoetti A; Nano R; Zelini P; Morbini P; Benericetti E; Ceroni M; Campoli M; Ferrone S
Clin Cancer Res; 2005 Dec; 11(23):8304-11. PubMed ID: 16322289
[TBL] [Abstract][Full Text] [Related]
11. Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21.
Maleno I; Cabrera CM; Cabrera T; Paco L; López-Nevot MA; Collado A; Ferrón A; Garrido F
Immunogenetics; 2004 Jul; 56(4):244-53. PubMed ID: 15258706
[TBL] [Abstract][Full Text] [Related]
12. Involvement of the chaperone tapasin in HLA-B44 allelic losses in colorectal tumors.
Cabrera CM; López-Nevot MA; Jiménez P; Garrido F
Int J Cancer; 2005 Feb; 113(4):611-8. PubMed ID: 15455354
[TBL] [Abstract][Full Text] [Related]
13. Loss of heterozygosity at 6p21 underlying [corrected] HLA class I downregulation in Chinese primary esophageal squamous cell carcinomas.
Yang Y; Zhang J; Miao F; Wei J; Shen C; Shen Y; Xie W
Tissue Antigens; 2008 Aug; 72(2):105-14. PubMed ID: 18721270
[TBL] [Abstract][Full Text] [Related]
14. Beta2-microglobulin gene mutation is not a common mechanism of HLA class I total loss in human tumors.
Fernández MA; Ruiz-Cabello F; Oliva MR; Cabrera T; Jimenez P; López Nevot MA; Garrido F
Int J Clin Lab Res; 2000; 30(2):87-92. PubMed ID: 11043502
[TBL] [Abstract][Full Text] [Related]
15. Methylation of the promoter of human leukocyte antigen class I in human esophageal squamous cell carcinoma and its histopathological characteristics.
Qifeng S; Bo C; Xingtao J; Chuanliang P; Xiaogang Z
J Thorac Cardiovasc Surg; 2011 Mar; 141(3):808-14. PubMed ID: 21335133
[TBL] [Abstract][Full Text] [Related]
16. MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma.
Atkins D; Breuckmann A; Schmahl GE; Binner P; Ferrone S; Krummenauer F; Störkel S; Seliger B
Int J Cancer; 2004 Mar; 109(2):265-73. PubMed ID: 14750179
[TBL] [Abstract][Full Text] [Related]
17. High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity.
Rodriguez T; Méndez R; Roberts CH; Ruiz-Cabello F; Dodi IA; López Nevot MA; Paco L; Maleno I; Marsh SG; Pawelec G; Garrido F
Cancer Immunol Immunother; 2005 Feb; 54(2):141-8. PubMed ID: 15592718
[TBL] [Abstract][Full Text] [Related]
18. HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15.
Garrido MA; Rodriguez T; Zinchenko S; Maleno I; Ruiz-Cabello F; Concha Á; Olea N; Garrido F; Aptsiauri N
Immunogenetics; 2018 Nov; 70(10):647-659. PubMed ID: 30145665
[TBL] [Abstract][Full Text] [Related]
19. HLA class I expression in bladder carcinomas.
Cabrera T; Pedrajas G; Cozar JM; Garrido A; Vicente J; Tallada M; Garrido F
Tissue Antigens; 2003 Oct; 62(4):324-7. PubMed ID: 12974799
[TBL] [Abstract][Full Text] [Related]
20. Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines.
Méndez R; Rodríguez T; Del Campo A; Monge E; Maleno I; Aptsiauri N; Jiménez P; Pedrinaci S; Pawelec G; Ruiz-Cabello F; Garrido F
Cancer Immunol Immunother; 2008 May; 57(5):719-29. PubMed ID: 17934731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
